A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer (ARMOR2)

This study is currently recruiting participants.
Verified March 2014 by Tokai Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Tokai Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01709734
First received: October 16, 2012
Last updated: March 27, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2014
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)